R.O. Mirimanoff

35.6k total citations · 4 hit papers
71 papers, 26.4k citations indexed

About

R.O. Mirimanoff is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Surgery. According to data from OpenAlex, R.O. Mirimanoff has authored 71 papers receiving a total of 26.4k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 25 papers in Genetics and 18 papers in Surgery. Recurrent topics in R.O. Mirimanoff's work include Glioma Diagnosis and Treatment (24 papers), Brain Metastases and Treatment (17 papers) and Advanced Radiotherapy Techniques (10 papers). R.O. Mirimanoff is often cited by papers focused on Glioma Diagnosis and Treatment (24 papers), Brain Metastases and Treatment (17 papers) and Advanced Radiotherapy Techniques (10 papers). R.O. Mirimanoff collaborates with scholars based in Switzerland, Netherlands and Belgium. R.O. Mirimanoff's co-authors include Roger Stupp, Michael Weller, J. Gregory Cairncross, Warren Mason, Thierry Gorlia, Robert C. Janzer, Martin J. van den Bent, Alba A. Brandes, Denis Lacombe and Elizabeth A. Eisenhauer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Neurology.

In The Last Decade

R.O. Mirimanoff

67 papers receiving 26.0k citations

Hit Papers

Radiotherapy plus Concomitant and Adjuvant T... 1985 2026 1998 2012 2005 2005 1985 2002 5.0k 10.0k 15.0k

Peers

R.O. Mirimanoff
Michael D. Prados United States
Robert C. Janzer Switzerland
Raymond Sawaya United States
Mark R. Gilbert United States
Anouk Allgeier Netherlands
Martin Taphoorn Netherlands
Allan H. Friedman United States
Michael D. Prados United States
R.O. Mirimanoff
Citations per year, relative to R.O. Mirimanoff R.O. Mirimanoff (= 1×) peers Michael D. Prados

Countries citing papers authored by R.O. Mirimanoff

Since Specialization
Citations

This map shows the geographic impact of R.O. Mirimanoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.O. Mirimanoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.O. Mirimanoff more than expected).

Fields of papers citing papers by R.O. Mirimanoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.O. Mirimanoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.O. Mirimanoff. The network helps show where R.O. Mirimanoff may publish in the future.

Co-authorship network of co-authors of R.O. Mirimanoff

This figure shows the co-authorship network connecting the top 25 collaborators of R.O. Mirimanoff. A scholar is included among the top collaborators of R.O. Mirimanoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.O. Mirimanoff. R.O. Mirimanoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boujelbene, N., Abdelmajid Khabir, Wendy Jeanneret Sozzi, R.O. Mirimanoff, & K. Khanfir. (2011). Clinical review – Breast adenoid cystic carcinoma. The Breast. 21(2). 124–127. 56 indexed citations
2.
Klein, Martin, L. Claassens, Neil K. Aaronson, et al.. (2010). An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. European Journal of Cancer. 46(6). 1033–1040. 272 indexed citations
3.
Collette, Sandra, Laurence Collette, Tom Budiharto, et al.. (2008). Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881–10882 ‘boost versus no boost’. European Journal of Cancer. 44(17). 2587–2599. 157 indexed citations
4.
Mak, Ki M., Robert C. Miller, Normand Laperrière, et al.. (2007). Outcomes and Prognostic Factors in Primary Intraocular Lymphoma: A Multicenter Rare Cancer Network Study. International Journal of Radiation Oncology*Biology*Physics. 69(3). S534–S535. 1 indexed citations
6.
Gorlia, Thierry, Martin J. van den Bent, Monika E. Hegi, et al.. (2007). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. The Lancet Oncology. 9(1). 29–38. 412 indexed citations
7.
Özsahin, Mahmut, Patrice Jichlinski, Damien C. Weber, et al.. (2006). Treatment of penile carcinoma: To cut or not to cut?. International Journal of Radiation Oncology*Biology*Physics. 66(3). 674–679. 35 indexed citations
8.
Özsahin, Mahmut, Michael Betz, Oscar Matzinger, et al.. (2006). Feasibility and Efficacy of Subcutaneous Amifostine Therapy in Patients With Head and Neck Cancer Treated With Curative Accelerated Concomitant-Boost Radiation Therapy. Archives of Otolaryngology - Head and Neck Surgery. 132(2). 141–141. 20 indexed citations
9.
Hegi, Monika E., Annie‐Claire Diserens, Thierry Gorlia, et al.. (2005). MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine. 352(10). 997–1003. 5232 indexed citations breakdown →
10.
Stupp, Roger, Warren Mason, Martin J. van den Bent, et al.. (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 352(10). 987–996. 15995 indexed citations breakdown →
11.
Voelter, Verena, et al.. (2005). L'annonce : d'une mauvaise nouvelle en oncologie : cancer. Revue Médicale Suisse. 1(20). 1350–1353. 6 indexed citations
12.
Senan, Suresh, Dirk De Ruysscher, P. Giraud, R.O. Mirimanoff, & Volker Budach. (2004). Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiotherapy and Oncology. 71(2). 139–146. 166 indexed citations
13.
Azria, D., Sophie Gourgou, Wendy Jeanneret Sozzi, et al.. (2004). Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. British Journal of Cancer. 91(7). 1251–1260. 71 indexed citations
14.
Eberhardt, Wilfried, Kathy S. Albain, Harvey I. Pass, et al.. (2003). Induction treatment before surgery for non-small cell lung cancer. Lung Cancer. 42(2). 9–14. 44 indexed citations
15.
Mirimanoff, R.O. & Roger Stupp. (2003). Radiotherapy in low-grade gliomas: cons. Seminars in Oncology. 30(6 Suppl 19). 34–38. 5 indexed citations
16.
Stupp, Roger, Robert C. Janzer, Monika E. Hegi, Jean‐Guy Villemure, & R.O. Mirimanoff. (2003). Prognostic factors for low-grade gliomas. Seminars in Oncology. 30(6 Suppl 19). 23–28. 44 indexed citations
17.
Stupp, Roger, Pierre-Yves Dietrich, Alessia Pica, et al.. (2002). Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide. Journal of Clinical Oncology. 20(5). 1375–1382. 630 indexed citations breakdown →
18.
Zografos, Léonidas, et al.. (1998). Radiotherapy of choroidal metastases. Radiotherapy and Oncology. 46(3). 263–268. 66 indexed citations
19.
Coucke, Philippe, et al.. (1997). Cell Line Specific Radiosensitizing Effect of Zalcitabine (2',3'-dideoxycytidine). Acta Oncologica. 36(2). 199–205. 1 indexed citations
20.
Mirimanoff, R.O.. (1994). Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): a review. Lung Cancer. 11. S79–S99. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026